November 10, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

Registration is OPEN for #NRG2026!

Join us in San Francisco, CA for the NRG 2026 Winter Meeting. The meeting will be held in-person, January 22-24, 2026, with select virtual sessions being held January 12-16, and January 20, 2026. Register soon to avoid the late registration fee!



More information | Agenda | Register

Winter 2026 Symposium – Theranostics: Precision Imaging Meets Targeted Therapy

Join us on in San Francisco, CA on Thursday, January 22, 2026 from 8am-12pm PT. The session will also be available virtually. This symposium will provide a comprehensive look at theranostics and radiopharmaceutical therapy. The program will begin with an introduction to the scientific foundations of radiopharmaceuticals, outlining how these agents differ from external beam radiation, and the practical considerations of imaging, dosimetry, and safe delivery. Participants will gain insight into the operational, regulatory, and infrastructural requirements needed to build a successful theranostics program within their institution.

Program Chair: Denise Fabian, MD and Co-Chairs: Charles Kunos, MD/PhD; Elise Kohn, MD

More information | Register

Reminder, the following clinical trials are open to enrollment. Please continue to review your patient population and discuss enrollment opportunities with your clinical teams. All protocol related documents are posted on CTSU.

NRG-GI008/CIRCULATE-North America is enrolling patients with stage III resected colon cancer or circulating tumor DNA positive (ctDNA+) Stage II or Stage IIIC resected colon cancer.

NRG-HN010: The HER2-positive cohort remains open and actively recruiting patients with salivary gland cancer.

NRG-LU007 is enrolling patients with extensive stage small-cell lung cancer. Only 17 more patients to complete the phase II portion of this trial!

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only. Read More

2. BIOSPECIMEN BANK

Update: Kit Shipments to Sites in Canada

The shipment of kits to sites in Canada has resumed. Sites no longer need to provide their FedEx account number when ordering kits, unless they request to have a kit shipped overnight. Please contact the NRG Biospecimen Bank in Columbus if you have any questions:

·        Phone: 614-722-2865

·        Email: BPCBank@nationwidechildrens.org

NRG Oncology Biospecimen Bank - Columbus Phone Number

The NRG Oncology Biospecimen Bank - Columbus is phasing out its 866 number. The number is still listed in some older protocols, but when contacting the Bank in Columbus, please use 614-722-2865. The 866 number will be deactivated at the end of November 2025.

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN011

The central lab, NYU Langone, will be closed on Thursday November 27, 2025, for Thanksgiving. Please plan tissue shipments accordingly.

4. CANCER PREVENTION & CONTROL

NRG-CC003: A summary of research results is available on the NRG Patient Study Webpage and the CTSU website. Sites, please share the summary of research results with study participants.

NRG-CC005/FORTE: FORTE Fridays Newsletter

NRG-CC005/FORTE: Clinical research professionals can sign up for NRG Oncology Weekly Broadcasts to receive monthly FORTE Fridays updates directly to your inbox (click here).

5. GENITOURINARY

NRG-GU011: Reusable Temperature Monitor Process Change

Starting November 24, 2025, McKesson Clinical Research Services will enhance its shipping process by introducing Tag-N-Trac reusable temperature monitoring devices in select 3L small parcel shipments, including those for NRG-GU011. A memo with further details is posted to CTSU.

6. HEAD & NECK

NRG-HN008

Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

7. GYNECOLOGIC

NRG-GY020: Approaching its final analysis. To provide the investigators with the most accurate information, please submit all overdue data and update any outstanding patient data queries by December 1, 2025.

NRG-GY026: Accruing patients of all stages and all histologic subtypes of endometrial cancer.

NRG-GY031: Please note there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

NRG-GY037 requires blocks to be submitted, but the study team recognizes variations in site operating procedures to release blocks. Please refer to the Letter to Pathologists in the Biospecimen Collection and Submission Manual. If your site is experiencing any issues with this requirement, please contact the study team as we can work with sites on a case-by-case basis to ensure patients have an opportunity to participate in this trial.

Study Overview Slides have been posted on CTSU.

8. VTOC TRAINING

For all NRG studies that use VTOC (Vision Tree Optimal Care): It has come to our attention that although Vision Tree has whitelisted their domain, Yahoo and AT&T have strong filters for spam that have been prohibiting participants from getting their emails. Please ask participants to 1) saves the email address (fasttrack@optimalcare.com) as a contact or 2) suggest an alternative email (i.e. gmail is a successful alternative) when setting up their accounts.



The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-CC015, NRG-GI011, NRG-GI012, NRG-GU015, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for November 12, 2025.

Investigator’s Brochure (IB*) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. NRG Oncology System Updates – Upcoming Participant Entry Downtime

NRG Oncology implemented system updates on November 9, 2025. This was the first of two NRG Oncology system updates that will be conducted before the end of the year 2025. The second update is confirmed to occur from Friday, November 21, 2025, at 5pm EST through Sunday, November 23, 2025. Please plan accordingly. Questions should be directed to support@nrgoncology.org.  

2. NRG Oncology Current Committee Leadership Openings

• Vice Chair, Publications Committee
  Deadline extension: Applications DUE November 18, 2025 - Read more & How to Apply

5. Thanksgiving Day Holiday Closure Information

Please see the memoranda posted on the CTSU website for Thanksgiving holiday closure information for the NRG Oncology Operations Offices, Statistics and Data Management Centers (SDMCs), Biospecimen Banks, and McKesson's Clinical Research Services.

6. REMINDER: Veterans Day Closure Information

Please note the following NRG Oncology locations will be closed on Tuesday, November 11, 2025, in observance of Veterans Day: Philadelphia East Operations Center, Buffalo SDMC, and the Biospecimen Bank in San Francisco. All other locations will be open during regular business hours.

7. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the scientific articles that appeared during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

PUBLISHED ARTICLES

Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH, McGarry RC, Kundapur V, Devisetty K, Wu A, McCarron EC, Pollock J, Kanner AA, Feldman DB, Pugh SL, Kachnic LA, Movsas B. "Hope" Drives Quality of Life in Patients With Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003. Int J Radiat Oncol Biol Phys. 2025 Nov 1;123(3):642-652. doi: 10.1016/j.ijrobp.2025.06.3884. Epub 2025 Jul 2. PMID: 40614783; PMCID: PMC12494067. Read more.



Galloway TJ, Pugh SL, Ridge JA, Nguyen-Tan PF, Rosenthal DI, Gillison M, Garden AS, Dunlap N, Caudell JJ, Jones CU, Bauman JR, Bahig H, Shenouda G, Currey A, Koyfman SA, Stokes WA, Read N, Lyness JA, Yom SS, Le QT. Long-Term Feeding Tube Use in Head and Neck Cancer Survivors-An Analysis of Patient- and Treatment-Related Factors. Int J Radiat Oncol Biol Phys. 2025 Nov 1;123(3):703-712. doi: 10.1016/j.ijrobp.2025.05.064. Epub 2025 Jun 3. PMID: 40473230; PMCID: PMC12396613. Read more.

Omuro A, DeAngelis LM, Polley MC, Correa D, Wefel JS, Bovi JA, Rosenblum M, Corn BW, Aneja S, Grommes C, Peereboom DM, Lallana EC, Werner-Wasik M, Rogers CL, Iwamoto FM, Yu HM, Donnelly ED, Struve TD, Won M, Mehta MP. Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma. Neuro Oncol. 2025 Nov 4:noaf221. doi: 10.1093/neuonc/noaf221. Epub ahead of print. PMID: 41189315. Read more.

Zumsteg ZS, Luu M, Fortpied C, Jang JK, Chen MM, Mallen-St Clair J, Walgama E, Le QT, Machtay M, Tribius S, Forastiere A, Wong S, Ozsahin EM, Gregoire V, Vermorken JB, Ho AS, Yom SS. Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931. Ann Oncol. 2025 Nov;36(11):1379-1388. doi: 10.1016/j.annonc.2025.07.004. Epub 2025 Jul 16. PMID: 40680992; PMCID: PMC12376881. Read more.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Radium Society (ARS) Annual Meeting; Apr 30-May 3, 2026; Newport Beach, CA

American Society of Clinical Oncology (ASCO) GI; Jan 8-10, 2026; San Francisco, CA

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL

San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX

Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI

Society of Surgical Oncology (SSO) – Advanced Cancer Therapies; Feb 14-16, 2026; Fort Lauderdale, FL

Society of Urologic Oncology (SUO); Dec 2-5, 2025; Dallas, TX

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 17-22, 2026; San Diego, CA; Due to publications committee Nov 4, 2025; Submission deadline Nov 18, 2025, 11:59 pm ET; LBA and Clinical Trials Jan 6, 2026, 11:59 pm ET

American Head & Neck Society (AHNS) Annual Meeting; Jul 18-22, 2026; Boston, MA; Due to publications committee Nov 21, 2025; Submission deadline Dec 5, 2025, 5:00 pm ET

American Society of Breast Surgeons (ASBrS); Apr 29-May 3, 2026; Seattle, WA; LBA Jan 9, 2026, 12:00 am PT

American Society of Clinical Oncology (ASCO); May 29-Jun 2, 2026; Chicago, IL; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 11:59 pm ET; LBA Mar 9, 2026, 12:00 pm ET (placeholder required)

American Society of Clinical Oncology (ASCO) GU; Feb 26-28, 2026; San Francisco, CA; LBA Nov 20, 2025, 12:00 pm ET (placeholder required)

American Society of Colon and Rectal Surgeons (ASCRS); May 9-12, 2026; Tampa, FL; LBA and Clinical Trials Jan 28, 2026

European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark; LBA Jan 15, 2026

American Society for Radiation Oncology (ASTRO); Boston, MA; Sep 27-30, 2026; Due to publications committee Feb 10, 2026; Submission deadline Feb 24, 2026; LBA Apr 20, 2026 (placeholder required)

ESMO (European Society for Medical Oncology) Breast; May 6-8, 2026; Berlin, Germany; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 21:00 CST; LBA Mar 31, 2026, 21:00 CST (placeholder required)

European Society for Radiotherapy and Oncology (ESTRO); May 15-19, 2026; Stockholm, Sweden; Submission deadline Nov 12, 2025; LBA Apr 8, 2026

Miami Breast Cancer Conference; Mar 5-8, 2026; Miami, FL; Due to publications committee Dec 22, 2025; Submission deadline Jan 5, 2026, 5:00 pm ET

Society of Surgical Oncology (SSO) – Annual Meeting; Mar 5-7; Phoenix, AZ; LBA Dec 1, 2025, 11:59 pm CT